422 related articles for article (PubMed ID: 30266159)
1. Nonalcoholic Liver Disease in Children and Adolescents.
Smith SK; Perito ER
Clin Liver Dis; 2018 Nov; 22(4):723-733. PubMed ID: 30266159
[TBL] [Abstract][Full Text] [Related]
2. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
Crespo M; Lappe S; Feldstein AE; Alkhouri N
Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
Satapathy SK; Sanyal AJ
Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study.
Barritt AS; Gitlin N; Klein S; Lok AS; Loomba R; Malahias L; Powell M; Vos MB; Weiss LM; Cusi K; Neuschwander-Tetri BA; Sanyal A
Contemp Clin Trials; 2017 Oct; 61():33-38. PubMed ID: 28735109
[TBL] [Abstract][Full Text] [Related]
5. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
[TBL] [Abstract][Full Text] [Related]
6. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Fukusato T
World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
[TBL] [Abstract][Full Text] [Related]
7. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
8. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
9. New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis.
Pydyn N; Miękus K; Jura J; Kotlinowski J
Pharmacol Rep; 2020 Feb; 72(1):1-12. PubMed ID: 32016853
[TBL] [Abstract][Full Text] [Related]
10. The pharmacological management of NAFLD in children and adolescents.
Liyanagedera S; Williams RP; Veraldi S; Nobili V; Mann JP
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1225-1237. PubMed ID: 28803504
[TBL] [Abstract][Full Text] [Related]
11. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
Kim SK; Kim KI; Kim SR
Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
[TBL] [Abstract][Full Text] [Related]
12. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
[TBL] [Abstract][Full Text] [Related]
13. Emerging New Diagnostic Modalities and Therapies of Nonalcoholic Fatty Liver Disease.
Lin CH; Kohli R
Curr Gastroenterol Rep; 2020 Aug; 22(10):52. PubMed ID: 32814993
[TBL] [Abstract][Full Text] [Related]
14. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
15. Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments.
Roeb E; Geier A
Z Gastroenterol; 2019 Apr; 57(4):508-517. PubMed ID: 30965381
[TBL] [Abstract][Full Text] [Related]
16. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
Duarte SMB; Stefano JT; Oliveira CP
Ann Hepatol; 2019; 18(3):416-421. PubMed ID: 31036494
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic fatty liver disease in children: recent practice guidelines, where do they take us?
Aggarwal A; Puri K; Thangada S; Zein N; Alkhouri N
Curr Pediatr Rev; 2014; 10(2):151-61. PubMed ID: 25088269
[TBL] [Abstract][Full Text] [Related]
18. Nonalcoholic fatty liver disease and cardiovascular disease.
Hyogo H; Chayama K; Yamagishi S
Curr Pharm Des; 2014; 20(14):2403-11. PubMed ID: 23844815
[TBL] [Abstract][Full Text] [Related]
19. Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease.
Della Corte C; Liccardo D; Ferrari F; Alisi A; Nobili V
Expert Opin Pharmacother; 2014 Dec; 15(17):2501-11. PubMed ID: 25219959
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in understanding and managing pediatric nonalcoholic fatty liver disease.
Vittorio J; Lavine JE
F1000Res; 2020; 9():. PubMed ID: 32509277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
